GVAX Receives Fast-Track Status
The FDA has granted Cell Genesys' GVAX immunotherapy fast track designation for prostate cancer. Two independent phase II trials in patients with hormone-refractory metastatic prostate cancer showed that median survival with GVAX compared favorably with that of patients treated with standard docetaxel (Taxotere)/prednisone in previous studies, the company said. Two phase III trials of GVAX have been initiated, VITAL-1 and VITAL-2. Each will enroll approximately 600 patients.
SOUTH SAN FRANCISCO, CalifThe FDA has granted Cell Genesys' GVAX immunotherapy fast track designation for prostate cancer. Two independent phase II trials in patients with hormone-refractory metastatic prostate cancer showed that median survival with GVAX compared favorably with that of patients treated with standard docetaxel (Taxotere)/prednisone in previous studies, the company said. Two phase III trials of GVAX have been initiated, VITAL-1 and VITAL-2. Each will enroll approximately 600 patients.
Articles in this issue
over 19 years ago
Triple-Negative Cancers More Common in Young Black Ptsover 19 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'over 19 years ago
Study to Examine Outcomes Disparities in Pediatric ALLover 19 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxover 19 years ago
CA4P Gets Orphan Drug Statusover 19 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsover 19 years ago
A Novel Brings a Cancer Research Laboratory to Lifeover 19 years ago
NCCN Reveals New Venous Thromboembolism Guidelineover 19 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caover 19 years ago
FDA Approves Dacogen for Treating All MDS SubtypesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Articles
- HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC
August 14th 2025
- INKmune Exhibits Favorable Safety in Metastatic CRPC
August 4th 2025